Tag: B.1.1.7 variant

1. A similar proportion of patients died within 28 days of randomization in both groups (high-titre convalescent plasma vs. usual care). 2. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Convalescent plasma is a...
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their second vaccine dose. 2. Substantial and consistent declines in COVID-19 incidence corresponded to greater vaccine coverage. Evidence Rating Level: 2 (Good) Study Rundown: Beyond clinical trials, there is growing evidence of the...
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The neutralizing titer of the vaccinated individuals was nine times lower against B.1.1.7 than the non-B.1.1.7 (Victoria) strain in vitro. Evidence Rating Level: 1 (Excellent) Study Rundown: As vaccines are distributed worldwide, concern...